Note: Bone marrow aspirate should be considered as the preferred sample type for AML Molecular panel testing. Peripheral blood can be used in lieu of bone marrow by clinicians should note that the level of circulating blasts may have an impact on the overall sensitivity of the assay.
3 mL CPD Bone Marrow (Preferred) 3 mL EDTA Blood 3 mL EDTA Bone Marrow 3 mL CPD Blood Turnaround Time: Between 1 week and 2 weeks Diagnostic Use and Interpretation Molecular variants in a number of genes have been detected in blasts from patients with Acute Myeloid Leukaemia (AML). The National Comprehensive Cancer Network guidelines for clinical practice in oncology recommends the molecular testing of FLT3, NPM1 and CEBPA genes in AML patients with a normal karyotype. The presence or absence of mutations in these genes can alter the prognosis and/or recommended treatment of patients with karyotype normal AML. Contact Information
To contact the Molecular Haematology team please call:
Auckland City Hospital (09) 307 4949 Lablink ext 22000 Prof. Peter Browett (Haematologist) ext 9090-86281 Nikhil Ghallayan (Section Leader) ext 22006 Molecular Haematology Lab ext 22005
For more inforamtion about the Molecular Haematology service at LabPLUS:
Molecular Haematology information page